Oscars are shaping up to be an exciting event with plenty of potential surprises, but there is one record that cannot be ...
The clinical Phase I study conducted in the NEX-22 project with good results and focus on the evaluation with Novo Nordisk has provided a good starting point for 2025. Significant events during the fo ...
Working with a contract drug manufacturing and testing firm in the United Kingdom, 25 to 30 healthy volunteers are now ...
Intra-Cellular Therapies' CAPLYTA is making waves in the antipsychotic market, gaining traction as a novel treatment for schizophrenia and bipolar de ...
Researchers from MBX Biosciences Inc. presented preclinical data on MBX-4291, a prodrug developed as a long-acting GLP-1/GIP co-agonist through MBX’s proprietary Precision Endocrine Peptide (PEP) ...
Assembly Biosciences (ASMB) announced promising interim results from its ongoing Phase 1a/b study of ABI-1179, an ...
Reports Q4 revenue $298M, consensus $259.3M. The company said, “Indivior (INDV) ended 2024 with a better-than-expected fourth ...
No. 2 / 2025Zealand Pharma Announces Financial Results for the Full Year 2024A transformational year with significant ...
The FDA has accepted a priority review of a new biannual HIV prevention injection, with a decision expected by June 19, 2025.
Many women spend decades using birth control of one kind or another, except for when they’re trying to conceive or are ...
Gilead (GILD) stock won an upgrade from Deutsche Bank on HIV treatment boost, while Merck (MRK) stock received a downgrade on ...
The FDA has accepted Gilead Sciences’ new drug application for lenacapavir as a long-lasting injectable to prevent HIV ...